Compulsin

Calcarea Carbonica, Coffea Cruda, Iodium, Mancinella, Physostigma Venenosum, Silicea, Ulmus Procera, Flos


Hellolife, Inc.
Human Otc Drug
NDC 49726-042
Compulsin also known as Calcarea Carbonica, Coffea Cruda, Iodium, Mancinella, Physostigma Venenosum, Silicea, Ulmus Procera, Flos is a human otc drug labeled by 'Hellolife, Inc.'. National Drug Code (NDC) number for Compulsin is 49726-042. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Compulsin drug includes Arabica Coffee Bean - 10 [hp_X]/1 Hippomane Mancinella Fruiting Leafy Twig - 10 [hp_X]/1 Iodine - 10 [hp_X]/1 Oyster Shell Calcium Carbonate, Crude - 10 [hp_X]/1 Physostigma Venenosum Seed - 10 [hp_X]/1 Silicon Dioxide - 10 [hp_X]/1 Ulmus Minor Flowering Twig - 10 [hp_X]/1 . The currest status of Compulsin drug is Active.

Drug Information:

Drug NDC: 49726-042
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Compulsin
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Calcarea Carbonica, Coffea Cruda, Iodium, Mancinella, Physostigma Venenosum, Silicea, Ulmus Procera, Flos
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Hellolife, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ARABICA COFFEE BEAN - 10 [hp_X]/1
HIPPOMANE MANCINELLA FRUITING LEAFY TWIG - 10 [hp_X]/1
IODINE - 10 [hp_X]/1
OYSTER SHELL CALCIUM CARBONATE, CRUDE - 10 [hp_X]/1
PHYSOSTIGMA VENENOSUM SEED - 10 [hp_X]/1
SILICON DIOXIDE - 10 [hp_X]/1
ULMUS MINOR FLOWERING TWIG - 10 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 15 Oct, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 23 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:HelloLife, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185371
N0000185375
N0000175629
N0000184306
M0000728
M0006342
M0016962
M0516536
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:3SW678MX72
HU6EYI2I1W
9679TC07X4
2E32821G6I
CJV9E9IIOA
ETJ7Z6XBU4
J3O020I532
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Dietary Proteins [CS]
Plant Proteins [CS]
Seed Storage Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Dietary Proteins [CS]
Increased Histamine Release [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
Seed Storage Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
49726-042-6060 TABLET in 1 BOTTLE, PLASTIC (49726-042-60)15 Oct, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Indications for use: for the temporary relief of symptoms such as: • nervous, repetitive thoughts • disproportionate fears • nervous, repetitive behaviors • apprehensiveness product indications are based solely on homeopathic materia medica and have not been evaluated by the fda.

Product Elements:

Compulsin calcarea carbonica, coffea cruda, iodium, mancinella, physostigma venenosum, silicea, ulmus procera, flos mannitol microcrystalline cellulose oyster shell calcium carbonate, crude oyster shell calcium carbonate, crude arabica coffee bean arabica coffee bean iodine iodine hippomane mancinella fruiting leafy twig hippomane mancinella fruiting leafy twig physostigma venenosum seed physostigma venenosum seed silicon dioxide silicon dioxide ulmus minor flowering twig ulmus minor flowering twig sorbitol crospovidone copovidone lactose monohydrate magnesium stearate h

Indications and Usage:

Directions: for the temporary relief of symptoms such as: • nervous, repetitive thoughts • disproportionate fears • nervous, repetitive behaviors • apprehensiveness product indications are based solely on homeopathic materia medica and have not been evaluated by the fda.

Warnings:

Warnings: stop use and as a doctor if symptoms persist or worsen. if pregnant or breastfeeding, ask a health professional before use.

Dosage and Administration:

Directions: dissolve under tongue. 30-50lb (13.6 kg-22.6kg): 1/2 tablet twice daily. 50lb+ (22.6kg): 1 tablet twice daily.

Package Label Principal Display Panel:

Package label display: ndc 49726-042-60 compulsin tablets nervous, repetitive thought/behavior relief homeopathic (otc) medicine 60 quick-dissolving tablets compulsin

Further Questions:

Questions: dist. by: hellolife, inc. 4635 40th st se grand rapids, mi 49512 www.hellolife.net


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.